Emerging targeted therapies for melanoma

Douglas B. Johnson*, Megan H. Pollack, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


ABSTRACT: Introduction: Melanoma is an aggressive cutaneous malignancy associated with poor response to traditional therapies. Recent regulatory approval for immune checkpoint inhibitors and agents targeting mutated BRAF has led to a tremendous expansion of effective treatment options for patients with advanced melanoma. Unfortunately, primary or acquired resistance develops in most patients, highlighting the need for additional therapies. Numerous genetic and other molecular features of this disease may provide effective targets for therapy development. Areas covered: This article reviews available melanoma treatments, including immune and molecularly-targeted therapies. We then discuss agents in development, with a focus on targeted (rather than immune) therapies. In particular, we discuss agents that block mitogen-activated protein kinase (MAPK) signaling, as well as other emerging approaches such as antibody-drug conjugates, cell-cycle targeting, and novel genetically-informed clinical trials. Expert opinion: Despite the incredible advances in melanoma therapeutics over the last several years, a clear need to develop more effective therapies remains. Molecularly-targeted therapy approaches will likely remain a cornerstone of melanoma treatment in parallel to immune therapy strategies.

Original languageEnglish (US)
Pages (from-to)195-207
Number of pages13
JournalExpert Opinion on Emerging Drugs
Issue number2
StatePublished - Apr 2 2016


  • binimetinib
  • BRAF
  • cobimetinib
  • glembatumumab vedotin
  • imatinib
  • KIT
  • Melanoma
  • NRAS
  • targeted therapy
  • trametinib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging targeted therapies for melanoma'. Together they form a unique fingerprint.

Cite this